Comments
on Thursday announced the grant of one product patent from Norway, another from South Korea and a third from Singapore for new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2027, 2034 and 2036, respectively, it said a notice to the stock exchanges. The granted claims of the patents are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s, attention deficient hyperactivity disorder, Huntington’s disease, narcolepsy, Parkinson’s and schizophrenia, respectively. Shares of Suven Life gained 0.5 per cent at ₹170.50 on the NSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.